A Phase 4 interventional study of Memantine in Alzheimer's Disease, sponsored by Merz Pharmaceuticals GmbH. Terminated at 1 site in Germany. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2011-09-26.
Sponsored by Merz Pharmaceuticals GmbH (part of Merz Pharma) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies testing memantine in Alzheimer Disease — 1 open to participants now, 2 under way, none of them phase 3. Memantine · Alzheimer Disease.
Among the 34 studies testing memantine in Alzheimer Disease, this one is the 31st largest by enrollment, is one of 5 that started in 2008, is one of 21 in phase 4, and was the 14th registered.
3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →1 of the 34 studies testing memantine in Alzheimer Disease is open now, in 1 country. Recruiting first, the newest first:
University Hospitals Cleveland Medical Center · Sites in United States
Ages 18–32
By country, each count listing its studies:
Memantine: first FDA approval 2003 (NAMENDA), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.
This study: 50 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 9 · Phase 4 21
First in 2003; this study’s year is marked. 5 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 19 is below the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 90 across the 34 interventional studies. Of the 28 that completed or were terminated, 15 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 34 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merz Pharmaceuticals GmbH, one of the names counted as Merz Pharma. Under that name alone:
Merz Pharmaceuticals GmbH is the lead sponsor of 61 studies on the registry; none are open to participants now.
Merz Pharma has 3 studies filed under Alzheimer Disease — fewer than ten, so there is no comparison to draw.
1 of the studies testing memantine in Alzheimer Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05063851University of VirginiaThe Use of Memantine for Prevention of Alzheimer's Disease | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 34 studies testing memantine in Alzheimer Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To investigate the potential to reduce concomitant antipsychotic medication use in subjects with moderate dementia of Alzheimer's type, treated with memantine.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Memantine
memantine tablets, twice a day (bid), for 20 weeks
Maximum Dose Reduction of Antipsychotics (AP) in Percent of Defined Daily Dose (DDD) From Baseline to a Post-baseline Visit at Which the Value of the Visual Analogue Scale (VAS) Compared With the Baseline Value Was =< 15 Percent.
VAS: see #8. Mean "percent of the total Defined Daily Dose (DDD)", averaged over one week, was calculated. Total DDD was calculated as sum of DDD for each AP drug. DDD is the assumed average maintenance dose per day defined by WHO. The reduction of AP Δ \[percent\] was calculated as a difference between the mean total DDD recorded at baseline and the mean total DDD recorded at the respective week. Measurements from those post-baseline visits were taken into account only when the value of the VAS was not substantially worse compared to baseline.
Time frame: Week 8-20 post baseline
Reduction of Antipsychotic Drug Dose From Baseline to Week 8, 12, 16 and/or 20.
See #1 and #8. Change of \<0 reveals a reduction of AP compared to baseline.
Time frame: Week 8-20 post Baseline
Change in the Mini-Mental State Examination (MMSE) Score Value From Baseline to Week 20.
MMSE is a brief, physician-administered scale, designed for measuring the cognitive functions, such as: orientation, memory, attention, naming, and comprehension. The scoring range of MMSE is 0 to 30 points. A score of 23 or lower is indicative of cognitive impairment. Change of \>0 reveals an improvement compared to baseline.
Time frame: Week 20 post baseline
Change of "Test for the Early Detection of Dementia With Discrimination From Depression [TE4D]" Score Value From Baseline to Week 4, 8, 12, 16, and/or 20 - First Part: Total Dementia
TE4D is a psychometric, physician-administered test that is used for both screening subjects with early dementia and monitoring the clinical progress of the disease. The first part consists of 9 items, which assess different symptoms associated with dementia such as memory, time-orientation, etc. The scoring range is 0 to 50 points. A score of 35 or lower is an indication of dementia. A change \>0 represents an improvement.
Time frame: Week 4-20 post baseline
Change of "Test for the Early Detection of Dementia With Discrimination From Depression [TE4D]" Score Value From Baseline to Week 4, 8, 12, 16, and/or 20 - Second Part: Total Depression
TE4D is a psychometric, physician-administered test that is used for both screening subjects with early dementia and monitoring the clinical progress of the disease. The second part consists of a proxy rating and a self-assessment rating. The scoring range of each rating is 1 to 10. The maximum total score of 10 corresponds to severe depression. A change \<0 reveals an improvement compared to baseline.
Time frame: Week 4-20 post Baseline
Change of Modified Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADLB19) Score Value From Baseline to Week 4, 8, 12, 16, and/or 20.
The modified ADCS-ADL19 is comprehensive battery of ADL questions aimed to measure the functional ability of subjects with Dementia of Alzheimer's type over a broad range of dementia severity. It has a scoring range of 0 to 54 with the lower scores indicating greater functional impairment. Each ADL item was rated from the highest level of independent performance to complete loss. Change of \>0 reveals an improvement compared to baseline.
Time frame: Week 4-20 post Baseline
Change of Nurses' Observation Scale for Geriatric Patients [NOSGER] Total Score Value From Baseline to Week 4, 8, 12, 16, and/or 20
NOSGER is a comprehensive scale, which contains 30 items of behavior, each rated on a 5-point scale according to the frequency of occurrence by direct observation. Item scores are summarized into 6 dimension scores: memory, instrumental activities of daily life, self-care, mood, social behavior, and disturbing behavior. The NOSGER has a scoring range of 30 to 150 with the higher scores indicating worse subject's status. The items in each group are rated for their frequency ranging from 1 (never) to 5 (always). A change of \<0 reveals an improvement compared to baseline.
Time frame: Week 4-20 post Baseline
Change in the VAS Score From Baseline to Week 8, 12, 16 and/or 20.
VAS is a report device to measure the subject's burden caused by behavioral symptoms. To measure the burden on the VAS only the first 3 items of the Neuropsychiatric Inventory (NPI) Questionnaire were considered (delusions, hallucinations (visual and auditory), and agitation / aggression). The VAS consists of a 100 mm horizontal line, anchored at the ends with the reference "not at all" and "extremely". The VAS score was determined by measuring in mm from the left hand end of the line to the point, where the investigator had marked the magnitude of a subject's burden.
Time frame: Week 8-20 post Baseline
| Milestone | Memantine |
|---|---|
| Started | 19 |
| Completed | 16 |
| Not completed | 3 |
| Withdrew: Adverse event | 2 |
| Withdrew: Withdrawal by subject | 1 |
VAS: see #8. Mean "percent of the total Defined Daily Dose (DDD)", averaged over one week, was calculated. Total DDD was calculated as sum of DDD for each AP drug. DDD is the assumed average maintenance dose per day defined by WHO. The reduction of AP Δ \[percent\] was calculated as a difference between the mean total DDD recorded at baseline and the mean total DDD recorded at the respective week. Measurements from those post-baseline visits were taken into account only when the value of the VAS was not substantially worse compared to baseline.
| Percent of daily dose [DDD] | Memantine |
|---|---|
| Maximum Dose Reduction of Antipsychotics (AP) in Percent of Defined Daily Dose (DDD) From Baseline to a Post-baseline Visit at Which the Value of the Visual Analogue Scale (VAS) Compared With the Baseline Value Was =< 15 Percent. | -13.9 ± 13.58 |
See #1 and #8. Change of \<0 reveals a reduction of AP compared to baseline.
| Percent of daily dose [DDD] | Memantine |
|---|---|
| Week 8 | -4.4 ± 5.53 |
| Week 12 | -8.2 ± 12.38 |
| Week 16 | -10.6 ± 13.49 |
| Week 20 | -14.9 ± 15.05 |
MMSE is a brief, physician-administered scale, designed for measuring the cognitive functions, such as: orientation, memory, attention, naming, and comprehension. The scoring range of MMSE is 0 to 30 points. A score of 23 or lower is indicative of cognitive impairment. Change of \>0 reveals an improvement compared to baseline.
| units on a scale | Memantine |
|---|---|
| Change in the Mini-Mental State Examination (MMSE) Score Value From Baseline to Week 20. | 0.9 ± 3.44 |
TE4D is a psychometric, physician-administered test that is used for both screening subjects with early dementia and monitoring the clinical progress of the disease. The first part consists of 9 items, which assess different symptoms associated with dementia such as memory, time-orientation, etc. The scoring range is 0 to 50 points. A score of 35 or lower is an indication of dementia. A change \>0 represents an improvement.
| units on a scale | Memantine |
|---|---|
| Week 4 | -2.3 ± 7.64 |
| Week 8 | -0.3 ± 5.31 |
| Week 12 | -1.3 ± 4.48 |
| Week 16 | 0.7 ± 5.39 |
| Week 20 | 1.4 ± 4.2 |
TE4D is a psychometric, physician-administered test that is used for both screening subjects with early dementia and monitoring the clinical progress of the disease. The second part consists of a proxy rating and a self-assessment rating. The scoring range of each rating is 1 to 10. The maximum total score of 10 corresponds to severe depression. A change \<0 reveals an improvement compared to baseline.
| units on a scale | Memantine |
|---|---|
| Week 4 | 2.5 ± 4.84 |
| Week 8 | 1.6 ± 3.97 |
| Week 12 | -0.1 ± 3.26 |
| Week 16 | -0.2 ± 2.07 |
| Week 20 | -0.4 ± 2.09 |
The modified ADCS-ADL19 is comprehensive battery of ADL questions aimed to measure the functional ability of subjects with Dementia of Alzheimer's type over a broad range of dementia severity. It has a scoring range of 0 to 54 with the lower scores indicating greater functional impairment. Each ADL item was rated from the highest level of independent performance to complete loss. Change of \>0 reveals an improvement compared to baseline.
| Units on a Scale | Memantine |
|---|---|
| Week 4 | -0.7 ± 6.33 |
| Week 8 | 2.2 ± 8.09 |
| Week 12 | 3.8 ± 11.07 |
| Week 16 | 3.8 ± 11.27 |
| Week 20 | 2.4 ± 11.08 |
NOSGER is a comprehensive scale, which contains 30 items of behavior, each rated on a 5-point scale according to the frequency of occurrence by direct observation. Item scores are summarized into 6 dimension scores: memory, instrumental activities of daily life, self-care, mood, social behavior, and disturbing behavior. The NOSGER has a scoring range of 30 to 150 with the higher scores indicating worse subject's status. The items in each group are rated for their frequency ranging from 1 (never) to 5 (always). A change of \<0 reveals an improvement compared to baseline.
| Units on a scale | Memantine |
|---|---|
| Week 4 | -0.4 ± 10.9 |
| Week 8 | -2.1 ± 10.31 |
| Week 12 | -5.4 ± 13.29 |
| Week 16 | -8.4 ± 18.74 |
| Week 20 | -7.9 ± 19.02 |
VAS is a report device to measure the subject's burden caused by behavioral symptoms. To measure the burden on the VAS only the first 3 items of the Neuropsychiatric Inventory (NPI) Questionnaire were considered (delusions, hallucinations (visual and auditory), and agitation / aggression). The VAS consists of a 100 mm horizontal line, anchored at the ends with the reference "not at all" and "extremely". The VAS score was determined by measuring in mm from the left hand end of the line to the point, where the investigator had marked the magnitude of a subject's burden.
| Units on a scale [cm] | Memantine |
|---|---|
| Week 8 | -1.5 ± 1.94 |
| Week 12 | -1.7 ± 2.53 |
| Week 16 | -1.2 ± 2.86 |
| Week 20 | -1.4 ± 2.46 |
Collected over All SAEs/AEs from baseline until 4 weeks after end of treatment (in total 20 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Memantine | — | 2/19 (10.5%) | 7/19 (36.8%) |
| Event | Memantine |
|---|---|
| DepressionPsychiatric disorders | 1/19 |
| AgitationPsychiatric disorders | 1/19 |
| Sleep DisturbancesPsychiatric disorders | 1/19 |
| Event | Memantine |
|---|---|
| FatigueGeneral disorders | 2/19 |
| AgitationPsychiatric disorders | 1/19 |
| AnxietyPsychiatric disorders | 1/19 |
| InsomniaPsychiatric disorders | 1/19 |
| ListlessPsychiatric disorders | 1/19 |
| Sleep-related eating disorderPsychiatric disorders | 1/19 |
| DiarrhoeaGastrointestinal disorders | 1/19 |
| Epigastric discomfortGastrointestinal disorders | 1/19 |
| Haemorrhoidal haemorrhageGastrointestinal disorders | 1/19 |
| NauseaGastrointestinal disorders | 1/19 |
| Age Continuous(years) | Memantine |
|---|---|
| Mean | 72.4 ± 9.7 |
| Age, Customized(participants) | Memantine |
|---|---|
| Between 50 and 85 years | 19 |
| Sex: Female, Male(Participants) | Memantine |
|---|---|
| Female | 10 |
| Male | 9 |
| Region of Enrollment(participants) | Memantine |
|---|---|
| Germany | 19 |
The record gives a start of Jul 2008, a primary completion of May 2009 and a completion of Jun 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2011, 2 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Memantine